An Observational Study of Patients Undergoing Therapy for Chronic Hepatitis B (HBV) Infection

• Efficacy of chronic HBV treatments as indicated by HBV DNA suppression measurements.[ Time Frame: Three year retrospective review. ]
  Efficacy will also be measured via ALT normalization, HBeAg loss, HBsAg loss, HBeAg and HBsAg seroconversion, development of HCC or evidence of hepatic decompensation.
• Safety of chronic HBV treatments on renal function as assessed by serum creatinine.[ Time Frame: Three year retrospective review. ]
  Renal function will also be measured via eGFRCG, proteinuria, albuminuria, serum phosphorus.
• Safety of chronic HBV treatments on bone density as assessed by DEXA scan.[ Time Frame: Three year retrospective review. ]
  Bone density will also be measured via medical history of osteopenia, osteoporosis, fractures.
• Safety of chronic HBV treatments as measured by co-morbidities and adverse events.[ Time Frame: Three year retrospective review. ]
  Safety will be assessed by reviewing medical history for evidence of adverse events, such as cardiovascular disease, diabetes mellitus, hypertension, hyperlipidemia.

The TARGET-HBV study engages an observational research design to conduct a comprehensive review of therapeutic outcomes for patients with chronic hepatitis B (HBV) who are currently taking tenofovir alafenamide (TAF) relative to those patients following other treatment regimens. The study will address important clinical questions regarding the management of HBV with TAF and other oral therapies by collecting and analyzing data from patients at academic and community medical centers. TARGET-HBV creates a robust database of real-world data regarding the natural history, management, and health outcomes related to TAF.

• Other: TAF
  Patients who are using TAF

• : tenofovir alafenamide
  Patients with a medication history of tenofovir alafenamide (TAF).